Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jennifer Conner

Physician Assistant, Medical Indianapolis, IN Physician Assistant

NPI 1669540969 CMS profile 11012747

7910 N Shadeland Ave, Indianapolis, IN 46250

Open in the dashboard

General payments

$98,112

881 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Conner of Indianapolis, IN is reported in the CMS Open Payments database as having received $98,112 across 881 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $33,981 249
2024 General $26,048 186
2023 General $23,090 196
2022 General $8,923 130
2021 General $6,070 120

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Conner
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Jennifer Conner were reported at $33,981. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Jennifer Conner Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $6,070 $156 $41–$563 $132
2022 $8,923 $185 $55–$649 $149
2023 $23,090 $199 $58–$717 $160
2024 $26,048 $206 $62–$740 $164
2025 $33,981 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Arcutis Biotherapeutics, Inc. $47,728 79 payments
  2. Novartis Pharmaceuticals Corporation $19,507 209 payments
  3. AbbVie, Inc. $5,511 109 payments
  4. Kowa Pharmaceuticals America, Inc. $4,158 4 payments
  5. Incyte Corporation $4,156 50 payments
  6. UCB, Inc. $2,161 37 payments
  7. Dermavant Sciences, Inc. $1,858 29 payments
  8. Journey Medical Corporation $1,758 7 payments
  9. LEO Pharma Inc. $1,588 12 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $1,459 13 payments
  11. Other $8,228 332 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $65,094 49 payments
  2. Food and Beverage $16,675 797 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,329 8 payments
  4. Travel and Lodging $7,124 19 payments
  5. Education $525 7 payments
  6. Honoraria $365 1 payment
Products named General payments · program years 2021–2025
  1. Zoryve Dermatology $33,661 54 payments
  2. ZORYVE Dermatology $4,158 4 payments
  3. RINVOQ $3,308 46 payments
  4. COSENTYX $2,701 75 payments
  5. Bimzelx $2,000 26 payments
  6. VTAMA $1,888 32 payments
  7. SPEVIGO $1,459 13 payments
  8. CIBINQO $1,395 65 payments
  9. OPZELURA $1,000 46 payments
  10. Otezla $887 37 payments
  11. Other $11,345 581 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

790

Median for Physician Assistant: 241

Drug cost

$607,131

Median for Physician Assistant: $4,110

Branded share of claims

14.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Otezla Apremilast Brand 49 $238,362
Humira(Cf) Pen Adalimumab Brand 13 $176,484
Cosentyx Unoready Pen Secukinumab Brand 12 $110,023
Dupixent Pen Dupilumab Brand 17 $62,515
Clobetasol Propionate Generic 102 $5,028
Fluorouracil Generic 33 $2,301
Ketoconazole Generic 141 $2,075
Tacrolimus Generic 12 $1,867
Clindamycin Phosphate Generic 39 $1,459
Fluocinonide Generic 33 $1,440

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$42,479

Of which drugs: $19,146

Medicare patients

220

Average age 75

Services billed

659

129 women, 91 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 26%
Chronic kidney disease 25%
Diabetes 24%
Depression 16%
Osteoporosis 16%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 20 28 $8,475

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zoryve
$17,107 — —
VTAMA
$471 — —
OPZELURA
$271 — —
TREMFYA
$216 — —
COSENTYX
$206 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

881 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record